Rainer Schulz

TL;DR: The aim of this review is to show the potential for developing cardioprotective drugs on the basis of endogenousCardioprotection by pre- and postconditioning and to review the evidence that comorbidities and aging accompanying coronary disease modify responses to ischemia/reperfusion and the cardiop Rotection conferred by preconditioning and post conditioning.

TL;DR: It is shown that female mice with a cardiomyocyte-specific deletion of stat3 develop PPCM, implying that inhibition of prolactin release may represent a novel therapeutic strategy for P PCM.

TL;DR: Evidence is provided for a uniform constitutive vascular NOS-activity across mammalian species by determining plasma nitrite concentration to be in a nanomolar range in a variety of species.

TL;DR: The critical need to take into account the presence of cardiovascular risk factors and concomitant medications when designing preclinical studies for the identification and validation of cardioprotective drug targets and clinical studies is emphasized.

TL;DR: Understanding of the underlying mechanisms must be improved to develop new therapeutic strategies to be applied at reperfusion with the ultimate aim of limiting the burden of ischaemic heart disease and potentially providing protection for other organs at risk of reperfusions injury, such as brain and kidney.